COSENTYX is the first and most prescribed treatment of its kind to target IL-17A, one of the multiple molecules in the body that may play a role in causing inflammation involved in psoriatic arthritis (PsA).

The work shown below specifically focus on the inflammatory, autoimmune condition that can affect both the joints and skin.

 Journal Ad